Source: European Medicines Agency (EU) Revision Year: 2020 Publisher: Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland
Atriance 5 mg/ml solution for infusion.
Pharmaceutical Form |
---|
Solution for infusion. Clear, colourless solution. |
Each ml of solution contains 5 mg of nelarabine.
Each vial contains 250 mg of nelarabine.
Excipient with known effect: Each ml of solution contains 1.725 mg (75 micromols) of sodium.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Nelarabine |
Nelarabine is a pro-drug of the deoxyguanosine analogue ara-G. Accumulation of ara-GTP in leukaemic blasts allows for preferential incorporation of ara-GTP into deoxyribonucleic acid (DNA) leading to inhibition of DNA synthesis. This results in cell death. Other mechanisms may contribute to the cytotoxic effects of nelarabine. In vitro, T-cells are more sensitive than B-cells to the cytotoxic effects of nelarabine. |
List of Excipients |
---|
Sodium chloride |
Clear glass (Type I) vial with a bromobutyl rubber stopper, and an aluminium seal with a red snap-off cap.
Each vial contains 50 ml of solution. Atriance is supplied in packs of 1 vial or 6 vials.
Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland
EU/1/07/403/001-002
Date of first authorisation: 22 August 2007
Date of latest renewal: 16 June 2017
Drug | Countries | |
---|---|---|
ATRIANCE | Austria, Canada, Estonia, Spain, Finland, France, Croatia, Ireland, Lithuania, Netherlands, Poland, Romania, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.